What is the significance of the FDA's approval of Rasonque (daraxonrasib) for metastatic pancreatic cancer?

The FDA approved Rasonque (daraxonrasib), a once-daily pill that blocks several forms of the RAS protein driving tumor growth in many pancreatic cancers, for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy; it is a first-in-class drug included in the FDA Commissioner's National Priority Voucher program—accelerating its review from the usual 10–12 months to just 1–2 months—and represents a significant advance in a disease with a five-year survival rate of about 13%, one of the lowest among major cancers.

What clinical evidence supported the FDA's approval of Rasonque?

The approval was based on a study of 500 adults with previously treated metastatic pancreatic adenocarcinoma—the most common type of pancreatic cancer—in which Rasonque improved overall survival to 13.2 months compared with 6.7 months on standard chemotherapy.

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

Aug 26, 2026

The FDA approved Revolution Medicines' Rasonque for metastatic pancreatic cancer, boosting median survival to 13.2 months versus 6.7 months on standard therapy. This first-in-class RAS inhibitor addresses a critical unmet medical need.

reuters

2026-06-01

Morning Bid: AI and 1984

2026-06-01

Experimental Pill Promises New Hope for Deadly Pancreatic Cancer

2026-08-26

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

FAQ